News
Axelar attends BIO-Europe partnering conference in Berlin, Germany
6 November 2017
Axelar AB will attend the 23rd annual BIO-Europe conference in Berlin, Germany on November 6-8, 2017 to meet with potential partners and investors. The BIO-Europe conference is Europe's largest partnering conference serving the global biotechnology …
Axelar attends BIO Investor Forum in San Francisco, USA
17 October 2017
Axelar AB will attend the BIO Investor Forum in San Francisco, USA on October 17-18, 2017 to meet with potential partners and investors. The BIO Investor Forum is an international biotech investor conference focused on early and established private …
Axelar AB welcomes Vidar Wendel-Hansen as Chief Medical Officer
1 September 2017
Vidar Wendel-Hansen has more than twenty years’ experience from pre-clinical and clinical development. He has served as Medical Director in both small biotech and large pharmaceutical companies. Dr Wendel-Hansen is also former Clinical Assessor at …
FDA Grants Orphan Drug Designation for AXL1717 for the Treatment of Glioma
28 July 2017
Axelar AB, a pharmaceutical company focused on developing targeted oral anti-cancer therapies for indications where there are significant unmet medical needs, announced today that the U.S. Food and Drug Administration (FDA) has granted an orphan …
EMA Grants Axelar Orphan Drug Designation for AXL1717 for the Treatment of Glioma
25 July 2017
Axelar AB today announced that the European Medicines Agency (EMA) has granted orphan designation to Axelar's drug candidate AXL1717 for the treatment of glioma. The EMA's orphan designation program is intended to encourage the development of …
Axelar attended 2017 BIO International Convention in San Diego, USA
26 June 2017
Axelar AB attended the 2017 BIO International Convention June 19-22 in San Diego, USA to meet with potential partners and investors. During the convention there were 16 123 attendees from 74 countries and 3 500 participating organizations took part …